Fate Therapeutics Inc (FATE)

[jondoeuk]

Milestones:

Launch registration study under RMAT for R/R aggressive BCL.
Initiate early-line aggressive BCL study for FT596 plus R-CHOP.
Generate clinical datasets with FT516/FT596, FT538, FT576 and FT819.

Generate dose-escalation datasets with FT538 plus mAb therapy.
Initiate dose-escalation study of FT536.
Complete IND-enabling studies of B7H3-targeted CAR program.

Nominate two novel multi-antigen targeted programs for solid tumours.
Complete preclinical development of ADR functionality to enable conditioning free cell therapy.
Complete preclinical development of TSR functionality to enhance TME persistence.

Submit IND to FDA for first iPSC-derived CAR-NK cell program under Janssen partnership.
Complete IND-enabling studies for iPSC-derived CAR-T cell program under Ono partnership.
Expand iPSC-derived product pipeline through additional collaborations.